Induction of the rabbit syndrome following coadministration of paroxetine, perphenazine, and amitriptyline

Clinical Neuropharmacology

Volumn 27, Issue 6, 2004, Pages 299-300

  Gourzis, Philippos ^a   Polychronopoulos, Panagiotis ^a   Argyriou, Andreas A ^a   Bakalidou, Constantina ^a   Beratis, Stavroula ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

Combination treatment; Paroxetine; Rabbit syndrome; Selective serotonin reuptake inhibitors

Indexed keywords

AMITRIPTYLINE; GLYCERYL TRINITRATE; PAROXETINE; PERPHENAZINE;

ADULT; ARTICLE; CASE REPORT; CLINICAL EXAMINATION; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; LIP; MAJOR DEPRESSION; NEUROLEPTIC MALIGNANT SYNDROME; PRIORITY JOURNAL; RABBIT SYNDROME;

AGED; AMITRIPTYLINE; BASAL GANGLIA DISEASES; DEPRESSION; DRUG COMBINATIONS; FEMALE; HUMANS; PAROXETINE; PERPHENAZINE; SEROTONIN UPTAKE INHIBITORS;

EID: 11244261304     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wnf.0000150870.52253.fe     Document Type: Article

References (15)

1. Leo RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry. 1996;57:449-454.
2. Schillevoort I, van Puijenbroek EP, de Boer A, et al. Extrapyramidal syndromes associated with selective serotonin reuptake inhibitors: a case-control study using spontaneous reports. Int Clin Psychopharmacol. 2002;17:75-79.
3. Yassa R, Lal S. Prevalence of the rabbit syndrome. Am J Psychiatry. 1986;143:656-657.
4. Jus K, Villenbuve A, Jus A. Tardive dyskinesia and the rabbit syndrome during wakefulness and sleep. Am J Psychiatry. 1972;129:143.
5. Fahn S, Elton R, members of the UPDRS Development Committee. Unified, Parkinson's Disease Rating Scale. In: Recent developments in Parkinson's disease. Vol. II. Macmillan Healthcare Information, New Jersey. 1987:153-163.
6. Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. Publication ADM 76-338. Washington, DC: US Department of Health, Education and Welfare, 1976;534-537.
7. Vandel P, Bonin B, Leveque E, et al. Tricyclic antidepressant-induced extrapyramidal side effects. Eur Neuropsychopharmacol. 1997;7:207-212.
8. Gill HS, deVane CL, Risch SC. Extrapyramidal symptoms associated with cyclic antidepressant treatment: a review of the literature and consolidating hypotheses. J Clin Psychopharmacol. 1997;17:377-388.
9. Brosen K, Hansen JG, Nielsen KK, et al. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol. 1993;44:349-355.
10. Preskorn SH, Alderman J, Chung M, et al. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol. 1994;14:90-98.
11. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry. 1996;153:311-320.
12. Ozdemir V, Naranjo CA, Herrmann N, et al. Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P450-′D6 inhibition in vivo. Clin Pharmacol Ther. 1997;62:334-347.
13. Casey DE. Rabbit syndrome. In: Anthony J, ed. Movement Disorders in Neurology and Neuropsychiatry. Blackwell Scientific; 1992:139-142.
14. Fornazzari L, Ichise M, Remington G, et al. Rabbit syndrome, antidepressant use and cerebral perfusion SPECT scan findings. J Psychiatry Neurosci. 1991;16:227-229.
15. Desmukh DK, Joshi VS, Agarwal MR. Rabbit syndrome - a rare complication of long term neuroleptic drugs. Br J Psychiatry. 1990;157:293.